NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children

Genetic Predisposition to Disease Clinical Trial

Official title:

NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03738098
• Other study ID #: GCO 16-1731
• Secondary ID: U01HG009610
• Status: Completed
• Phase: N/A
• Start date: January 30, 2019
• Est. completion date: April 28, 2022

Study information

• Verified date: December 2023
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The NYCKidSeq program will significantly advance the implementation of genomic medicine, particularly for children, young adults and their families in Harlem and the Bronx. The study will assess the clinical utility of genomic medicine in three broad areas of pediatric disorders, while engaging a range of providers and community advisors to overcome the well-documented barriers to inclusion of underserved and underrepresented populations in genomic research. The study will also include testing, analyzing, and implementing a novel communication tool, Genomic Understanding, Information and Awareness (GUÍA), to facilitate the return of genomic test results. The use of GUÍA will enhance the understanding of these genomic testing results by families, patients, and care providers at all levels of expertise, in two health systems. Healthcare system leadership will be engaged to provide insights into their readiness for genomic implementation. Overall, the NYCKidSeq program will inform the genomics and clinical communities about how to implement genomic medicine in a diverse population in a clinically useful, technologically savvy, culturally sensitive, and ethically sound manner.

Description:

NYCKidSeq is a research study using a randomized controlled trial (RCT) design to compare the use of GUÍA in a traditional genetic counseling return of results session to facilitate the return of genomic results compared to a traditional return of results counseling session. GUÍA will be an enhanced, personalized electronic version focused on helping patients understand their own genomic results. The researchers will also evaluate the clinical utility of whole genome sequencing (WGS) compared to targeted gene panels (TGP) in children with suspected genetic etiology of their neurologic disorders, primary immunodeficiencies, and cardiovascular disorders with the goal of detecting the mutated gene(s) responsible for their disorder.

1100 referred children Mount Sinai and Albert Einstein College of Medicine/Montefiore Hospital (Einstein/Montefiore) will be enrolled and randomized to either traditional genetic counseling (standard of care) or traditional genetic counseling plus GUÍA. The researchers will assess parents' perceived and subjective understanding of results as well as their adherence to follow-up recommendation (primary and secondary outcomes) through the use of parental surveys at three time points. The RCT will occur in the context of performing WGS and TGP for diagnostic purposes in 1,130 children.

Participants will have three study visits (Baseline, ROR1, and ROR2) over a nine-month period. At the baseline visit, families will receive pre-test counseling and will complete a survey. Blood will be collected from all study participants and from each biological parent (if available) to assist with interpretation of genomic results. Samples will undergo WGS and TGP. Approximately three months later, results will be returned and explained via one of the two study arms - traditional genetic counseling versus genetic counseling with GUÍA, and parents will be asked to complete the ROR1 survey. Six months later, they will be asked to complete the ROR2 survey. The length of a subject's participation will be a minimum of nine months to a maximum of 27 months, depending on the time of study entry; participation after the initial nine months will consist solely of chart and data review. Over the initial 9-month period the investigators are studying the experiences and understanding of parents of children who receive sequencing to help understand how best to implement genomic medicine in a diverse population.

GUÍA will be an enhanced, personalized electronic version of a flip chart, which is the type of tool most commonly used in routine genetic counseling. In the third year of the study, the study team anticipates to have the tool integrated into EPIC. There are no tools yet focused on this complex information, specifically on helping patients understand their own genomic results.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 650
• Est. completion date: April 28, 2022
• Est. primary completion date: April 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Infants, children and young adults up to and including 21 years of age; young adults (18-21) who are cognitively intact may participate in this study, but their parent(s) or legal guardian(s) must also agree to participate

• English- or Spanish-speaking parent or legal guardian capable of providing informed consent, participating in surveys, and able to see GUIA;

• Currently undiagnosed, likely genetic* cause of neurologic, immunologic, or cardiac disorders (*as determined by disorder-specific criteria in Section IIIc. and phenotype checklist Appendix w.)

• Followed by a physician in the MS or EM systems;

• Willing and able to return for each study visit (not moving out of the area within nine months)

• If targeted gene panels and/or whole exome sequencing were previously done, results must have been returned at least three months before enrollment;

• If targeted gene panels and/or whole exome sequencing were previously done, results must have been negative, or identified only one variant in a potentially causative autosomal recessive gene, and

• If the parents received genetic counseling about this child, themselves, or a family member, the last genetic counseling session must have been at least three months before enrollment (*if testing was within 6-months their recruitment will be held until they 3-months or after)

• If patients have undergone karyotyping alone, we do not have to wait 3 months prior to inclusion.

Exclusion Criteria:

• The referred child is currently participating in a different genetic sequencing study, that includes genetic counseling and/or return of results before the participant's ROR2 visit.

• The referred child has a known or likely molecular genetic diagnosis for their neurologic, immunologic, or cardiac disorder.

• The referred child has had a bone-marrow transplant.

Related Conditions & MeSH terms

• Genetic Diseases, Inborn
• Genetic Predisposition to Disease

Intervention

Behavioral:
• Standard of Care
Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
• GUÍA
GUÍA for the ROR1 visit.

Locations

Country	Name	City	State
United States	Albert Einstein College of Medicine/Montefiore	Bronx	New York
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (5)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai	Albert Einstein College of Medicine, National Human Genome Research Institute (NHGRI), National Institute on Minority Health and Health Disparities (NIMHD), New York Genome Center

Country where clinical trial is conducted

United States, 

References & Publications (2)

Abul-Husn NS, Marathe PN, Kelly NR, Bonini KE, Sebastin M, Odgis JA, Abhyankar A, Brown K, Di Biase M, Gallagher KM, Guha S, Ioele N, Okur V, Ramos MA, Rodriguez JE, Rehman AU, Thomas-Wilson A, Edelmann L, Zinberg RE, Diaz GA, Greally JM, Jobanputra V, Su — View Citation

Suckiel SA, Kelly NR, Odgis JA, Gallagher KM, Sebastin M, Bonini KE, Marathe PN, Brown K, Di Biase M, Ramos MA, Rodriguez JE, Scarimbolo L, Insel BJ, Ferar KDM, Zinberg RE, Diaz GA, Greally JM, Abul-Husn NS, Bauman LJ, Gelb BD, Horowitz CR, Wasserstein MP — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perceived understanding of genomic testing results	Perceived understanding of genomic testing results. Scale from 1 (very little or none of it) to 5 (understood almost all or all of it) at 3 months	3 months
Primary	Perceived understanding of genomic testing results	Perceived understanding of genomic testing results. Scale from 1 (very little or none of it) to 5 (understood almost all or all of it) at 3 months	9 months
Primary	Perceived confidence explaining genomic testing results	Perceived confidence explaining child's genetic test results. Scale from 1 (completely confident) to 5 (not confident at all) at 3 months	3 months
Primary	Perceived confidence explaining genomic testing results	Perceived confidence explaining child's genetic test results. Scale from 1 (completely confident) to 5 (not confident at all) at 9 months	9 months
Secondary	Objective understanding of genomic testing results	Participants will answer yes, no, or not sure/don't remember at 3 months	3 months
Secondary	Objective understanding of genomic testing results	Participants will answer yes, no, or not sure/don't remember at 9 months	9 months
Secondary	Understanding of recommended medical follow up and actionability of genomic results	Participants will answer yes, no, or I don't know/don't remember/unsure	3 months
Secondary	Adherence to medical follow up recommendations	Participants will answer yes, not yet but plan to; or no, and don't plan to; or don't know	9 months
Secondary	Percent of participants with definitive or likely positive diagnoses	Diagnostic results assessed by percent of participants with definitive or likely positive diagnoses	up to 27 months
Secondary	Time to diagnosis of WGS and TGP	Time to diagnosis comparison of WGS and TGP	up to 27 months
Secondary	Concordance of WGS and TGP results	Percent of agreement between WGS and TGP testing results	up to 27 months

External Links

•   Clinical Sequencing Evidence-Generating Research (CSER) Website